• Erlotinib Workflows for EGFR Research

  2026-08-25

  Build reproducible EGFR phosphorylation, proliferation, and apoptosis experiments with Erlotinib (NSC 718781). This guide also shows how to use EGFR blockade as a mechanistic comparator when studying SCUBE3-driven oncogenic signaling and immune suppression.

• Belinostat (PXD101) Cancer Assay Workflow

  2026-08-25

  Build a more informative Belinostat workflow by separating growth arrest from cell killing across bladder and prostate cancer models. This practical guide combines HDAC biology, dose–response design, orthogonal readouts, formulation control, and troubleshooting for reproducible preclinical studies.

• BIRB 796 (Doramapimod) for Reliable Assays

  2026-08-24

  This scenario-based guide shows how BIRB 796 (Doramapimod), SKU A5639, can support interpretable viability, apoptosis, and cytokine experiments through selective p38α MAPK inhibition. It covers controls, solvent handling, dose optimization, mechanistic interpretation, and practical vendor-selection criteria.

• HyperFluor™ 594 Goat Anti-Rabbit IgG: Assay Design

  2026-08-24

  Learn how a goat anti-rabbit IgG secondary antibody can translate causal atherosclerosis evidence into rigorous imaging, tissue, flow cytometry, and ELISA workflows. This guide connects ISG20 validation, spectral planning, controls, and application-specific optimization.

• MDV3100: AR Heterogeneity in CRPC Models

  2026-08-23

  MDV3100 (Enzalutamide) is a powerful tool for investigating androgen receptor dependence in prostate cancer. This article presents an AR-state-aware framework for interpreting apoptosis, resistance, and treatment-response assays in castration-resistant prostate cancer models.

• AL-8810: Prostaglandin F2α Antagonist Workflow

  2026-08-22

  AL-8810 enables controlled dissection of FP receptor signaling across endometrial, vascular, smooth muscle, fibroblast, and ocular cell models. This practical guide combines potency-aware dosing, pathway-specific readouts, and troubleshooting strategies for reproducible prostaglandin F2α antagonist research.

• IAM-LC vs LEKC for Pulmonary Drug Permeability

  2026-08-22

  A 2024 Journal of Chromatography A study provides the first direct comparison of immobilised artificial membrane liquid chromatography and liposome electrokinetic capillary chromatography for biomimetic drug–membrane partitioning and pulmonary permeability assessment. LEKC more closely modeled apparent lung permeability, whereas IAM LC offered broader compound coverage, simpler implementation, and stronger suitability for high-throughput screening.

• Trelagliptin and Adipocyte Insulin Resistance

  2026-08-21

  The reference study uses differentiated 3T3-L1 adipocytes to connect trelagliptin succinate with improved glucose uptake, GLUT4 membrane localization, and PI-3K/AKT/IRS-1 signaling. Its findings support a cellular mechanism for improved insulin sensitivity while also highlighting the limits of inferring therapeutic effects from an in vitro adipocyte model.

• Ceftazidime Workflow for Gram-Negative Research

  2026-08-20

  Ceftazidime provides a practical phenotype-first tool for studying Pseudomonas aeruginosa, β-lactamase-producing Enterobacteriaceae, and resistance transmission. This workflow combines reproducible susceptibility testing with plasmid localization, conjugation, and genotype–phenotype troubleshooting.

• Methylprednisolone: From Inflammation to Bone

  2026-08-20

  Methylprednisolone is a synthetic glucocorticoid receptor agonist that connects cytokine control with steroid-induced skeletal injury models. This article presents a decision framework for selecting assays, interpreting bone outcomes, and translating glucocorticoid exposure into reproducible research questions.

• Dovitinib and the Next Wave of Translational Oncology

  2026-08-19

  Dovitinib (TKI-258) offers translational researchers a powerful way to interrogate convergent RTK signaling, apoptosis, and tumor-context dependencies. This thought-leadership guide connects its multitarget pharmacology with practical validation strategies, multiple myeloma research, hepatocellular carcinoma treatment research, and a cautious framework for exploring immune-related biology.

• BIRB 796 for p38α MAPK Research

  2026-08-19

  BIRB 796 (Doramapimod) combines high p38α selectivity with an allosteric, slow-dissociation mechanism suited to cytokine, phospho-signaling, and apoptosis workflows. This guide translates its properties into practical assay design, control selection, and troubleshooting for inflammation research and arthritis model studies.

• Redox Intelligence for Translational Nanomedicine

  2026-08-18

  A strategic guide to using 2',7'-Dichlorofluorescein diacetate for intracellular ROS measurement, with mechanistic context from an adaptive pancreatic cancer nanocarrier study. The article explains what the signal can reveal, where interpretation can fail, and how to connect oxidative stress data to translational decisions.

• IRG1–Itaconic Acid Control of TBK1 and Type I IFN

  2026-08-18

  A 2025 Cell Reports study identifies itaconic acid as a metabolic feedback signal that restrains TBK1-dependent type I interferon production by alkylating TBK1 at Cys605 and disrupting its dimerization. The work also introduces ITA-5 and ITA-9 as itaconic acid-based candidate inhibitors for limiting excessive interferon-driven inflammation.

• AKT Inhibitors: Class-Specific Activity and Resistance

  2026-08-17

  This systematic study shows that ATP-competitive and allosteric AKT inhibitors cannot be interpreted as interchangeable tools: they differ in catalytic and non-catalytic effects, mutation sensitivity, and phosphoproteomic consequences. Its integrated pharmacology, structural analysis, and combination-screening strategy provides a framework for selecting AKT inhibitors in context-specific oncology research.

555 records 7/37 page Previous Next First page 上5页 678910 下5页 Last page